Nephros Inc (NEPH)
Official siteHEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ
Market Cap: $33.15M
Last updated: Nov 17, 2026 at 11:00 AM ET
Nephros Inc (NEPH) Earnings: Report Dates and Results
Nephros (NEPH) is expected to report earnings on Mar 10, 2027. In the quarter ended Sep 30, 2026, Nephros reported EPS of $0.05, above the $0.02 estimate. It beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
NEPH has an expected report date of Mar 10, 2027.
NEPH Earnings Call
The latest NEPH earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 30 quarters below that had an estimate, NEPH beat 14, missed 11 and matched 5. Revenue for the quarter ended Sep 30, 2026 was $5.62M, up 18.1% from $4.76M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.05 | $0.02 | N/A | +150.00% | Beat | +66.7% | 1 | 1 up, 1 down | Nov 5, 2026 | $5.62M |
| Jun 30, 2026 | $0.06 | $0.01 | -$0.01 - $0.01 | +500.00% | Beat | +200.0% | 3 | 1 up, 1 down | Aug 6, 2026 | $6.02M |
| Mar 31, 2026 | $0.01 | $0.01 | $0.01 - $0.01 | 0.00% | In line | -80.0% | 2 | 0 up, 1 down | May 7, 2026 | $5.21M |
| Dec 31, 2025 | $0.01 | -$0.01 | N/A | +200.00% | Beat | -66.7% | 2 | 0 up, 1 down | Mar 12, 2026 | $4.73M |
| Sep 30, 2025 | $0.03 | -$0.02 | -$0.02 - -$0.02 | +250.00% | Beat | +50.0% | 2 | 0 up, 1 down | Nov 6, 2025 | $4.76M |
| Jun 30, 2025 | $0.02 | -$0.02 | -$0.03 - -$0.02 | +200.00% | Beat | N/A | 2 | 0 up, 2 down | Aug 7, 2025 | $4.42M |
| Mar 31, 2025 | $0.05 | -$0.01 | -$0.02 - $0.01 | N/A | N/A | N/A | 2 | 0 up, 1 down | May 15, 2025 | $4.88M |
| Dec 31, 2024 | $0.03 | -$0.02 | -$0.02 - -$0.01 | +300.00% | Beat | N/A | 2 | 0 up, 0 down | Mar 24, 2025 | $3.87M |
| Sep 30, 2024 | $0.02 | -$0.02 | -$0.02 - -$0.02 | +200.00% | Beat | N/A | 2 | 0 up, 0 down | Nov 7, 2024 | $3.52M |
| Jun 30, 2024 | -$0.03 | -$0.01 | N/A | -200.00% | Miss | N/A | N/A | 0 up, 0 down | Aug 8, 2024 | $3.25M |
| Mar 31, 2024 | -$0.02 | -$0.04 | -$0.06 - -$0.02 | +50.00% | Beat | N/A | 2 | 0 up, 0 down | May 9, 2024 | $3.52M |
| Dec 31, 2023 | -$0.06 | -$0.02 | -$0.04 - -$0.01 | -200.00% | Miss | N/A | 2 | 0 up, 0 down | Mar 7, 2024 | $3.25M |
| Sep 30, 2023 | -$0.02 | -$0.05 | -$0.08 - -$0.05 | +60.00% | Beat | N/A | 2 | 0 up, 0 down | Nov 8, 2023 | $3.74M |
| Jun 30, 2023 | -$0.04 | -$0.05 | -$0.06 - -$0.05 | +20.00% | Beat | N/A | 2 | 0 up, 0 down | Aug 9, 2023 | $3.54M |
| Mar 31, 2023 | -$0.03 | -$0.02 | -$0.02 - -$0.02 | -50.00% | Miss | N/A | 1 | 0 up, 0 down | May 10, 2023 | $3.70M |
| Dec 31, 2022 | -$0.10 | -$0.06 | -$0.07 - -$0.06 | -66.67% | Miss | N/A | 2 | 0 up, 0 down | Mar 8, 2023 | $2.56M |
| Sep 30, 2022 | -$0.31 | -$0.11 | -$0.12 - -$0.10 | -181.82% | Miss | N/A | 3 | 0 up, 0 down | Nov 2, 2022 | $2.41M |
| Jun 30, 2022 | -$0.12 | -$0.14 | -$0.16 - -$0.14 | +14.29% | Beat | N/A | 2 | 0 up, 0 down | Aug 10, 2022 | $2.85M |
| Mar 31, 2022 | -$0.20 | -$0.11 | -$0.13 - -$0.08 | -81.82% | Miss | N/A | 3 | 0 up, 0 down | May 4, 2022 | $2.16M |
| Dec 31, 2021 | -$0.11 | -$0.11 | -$0.14 - -$0.10 | 0.00% | In line | N/A | 3 | N/A | Feb 23, 2022 | N/A |
| Sep 30, 2021 | -$0.12 | -$0.11 | -$0.11 - -$0.10 | -9.09% | Miss | N/A | 2 | N/A | Nov 4, 2021 | $2.58M |
| Jun 30, 2021 | -$0.12 | -$0.11 | -$0.12 - -$0.10 | -9.09% | Miss | N/A | 3 | N/A | Aug 5, 2021 | $2.27M |
| Mar 31, 2021 | -$0.11 | -$0.11 | -$0.14 - -$0.09 | 0.00% | In line | N/A | 3 | N/A | May 6, 2021 | $5.47M |
| Dec 31, 2020 | -$0.08 | -$0.11 | -$0.12 - -$0.10 | +27.27% | Beat | N/A | 3 | N/A | Mar 1, 2021 | $2.33M |
| Sep 30, 2020 | -$0.14 | -$0.14 | -$0.16 - -$0.11 | 0.00% | In line | N/A | 3 | N/A | Nov 5, 2020 | $2.12M |
| Jun 30, 2020 | -$0.19 | -$0.15 | -$0.17 - -$0.12 | -26.67% | Miss | N/A | 3 | N/A | Aug 5, 2020 | $1.58M |
| Mar 31, 2020 | -$0.13 | -$0.09 | N/A | -44.44% | Miss | N/A | 2 | N/A | May 6, 2020 | $2.53M |
| Dec 31, 2019 | -$0.02 | -$0.11 | -$0.15 - -$0.08 | +81.82% | Beat | N/A | 3 | N/A | Feb 27, 2020 | N/A |
| Sep 30, 2019 | -$0.10 | -$0.10 | -$0.12 - -$0.07 | 0.00% | In line | N/A | 3 | N/A | Nov 6, 2019 | N/A |
| Jun 30, 2019 | -$0.14 | -$0.18 | N/A | +22.22% | Beat | N/A | N/A | N/A | Aug 7, 2019 | $2.31M |
| Mar 31, 2019 | -$0.18 | -$0.09 | N/A | -100.00% | Miss | N/A | N/A | N/A | May 8, 2019 | $1.77M |
| Dec 31, 2018 | -$0.09 | N/A | N/A | N/A | N/A | -550.0% | N/A | N/A | Mar 12, 2019 | $1.61M |
| Sep 30, 2018 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 8, 2018 | $1.72M |
| Jun 30, 2018 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 8, 2018 | $1.37M |
| Mar 31, 2018 | -$0.03 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 9, 2018 | $985000 |
| Dec 31, 2017 | $0.02 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Feb 26, 2018 | $1.30M |
| Sep 30, 2017 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Nov 9, 2017 | $916000 |
| Jun 30, 2017 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Aug 8, 2017 | $859000 |
| Mar 31, 2017 | -$0.01 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | May 9, 2017 | $734000 |
| Dec 31, 2016 | -$0.12 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 20, 2017 | $746000 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was $0.11. It was -$0.52 for the year ended Dec 31, 2016, the oldest of the 9 fiscal years below with reported EPS.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | $0.11 | N/A |
| Dec 31, 2024 | Not reported | N/A |
| Dec 31, 2023 | -$0.15 | N/A |
| Dec 31, 2022 | -$0.73 | N/A |
| Dec 31, 2021 | -$0.46 | N/A |
| Dec 31, 2020 | -$0.54 | N/A |
| Dec 31, 2019 | -$0.44 | N/A |
| Dec 31, 2018 | -$0.14 | N/A |
| Dec 31, 2017 | -$0.01 | N/A |
| Dec 31, 2016 | -$0.52 | N/A |
Earnings Calls
The 7 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,800 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,811 | 6 | |
| 2026Q2 | Jun 30, 2026 | 4,626 | 7 | |
| 2026Q1 | Mar 31, 2026 | 4,603 | 7 | |
| 2025Q4 | Dec 31, 2025 | 3,411 | 6 | |
| 2025Q3 | Sep 30, 2025 | 4,894 | 7 | |
| 2024Q3 | Sep 30, 2024 | 3,515 | 7 | |
| 2024Q2 | Jun 30, 2024 | 2,408 | 5 |
2026Q3 Earnings Call
Opening remarks
Kirin Smith Conference Call Moderator Thank you, everyone, and good afternoon. This is Kirin Smith with PCG Advisory. Thank you all for participating in Nephros' third quarter 2026 conference call. Before we begin, I would like to caution that comments made during this conference call by management will contain forward-looking statements regarding the operations and future results of Nephros. I encourage you to review Nephros' filings with the Securities and Exchange Commission, including, without limitation, the company's Forms 10-K and 10-Q, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements. Factors that may affect the company's results include, but are not limited to, Nephros' ability to successfully, timely, and cost-effectively market and sell its products and service offerings; the rate of adoption of its products and services by hospitals and other healthcare providers; the success of its commercialization efforts; and the effect of existing and new regulatory requirements on Nephros' business, as well as other economic and competitive factors. The content of this conference call contains time-sensitive information that is accurate only as of the date of the live call, today, November 6, 2026. The company undertakes no obligation to revise or update any statements to reflect events or circumstances after the date of this conference call, except as required by law. I would now like to turn the call over to Nephros' President and Chief Executive Officer, Robert Banks. Robert, please go ahead.
Robert Banks President and Chief Executive Officer Thank you, Kirin, and good afternoon, everyone. The third quarter of 2026 was another strong quarter for Nephros, and more importantly, provides additional evidence of the durability of the growth we have been building over the last several years. We generated approximately $5.6 million in revenue, an increase of 18% over the third quarter of 2025. This followed the record $6 million we reported in the second quarter. I think that sequence is important. A record quarter is exciting. Following a record quarter with another quarter of strong double-digit year-over-year growth tells us much more about the underlying business. For the first nine months of 2026, revenue reached approximately $16.9 million, an increase of 20% over the same period last year. Core programmatic revenue increased 19% over that nine-month period. Importantly, this is profitable revenue growth, where net income and adjusted EBITDA increased to approximately $500,000 and approximately $600,000, respectively. Our trailing 12-month revenue has now surpassed $21 million. When you look at those results together, I believe they demonstrate that Nephros is becoming a larger, stronger, and increasingly durable business. Our core programmatic business remains the foundation of that growth. Programmatic product revenue increased approximately 8% during the third quarter compared with last year.
Frequently Asked Questions About NEPH
When is Nephros's next earnings date?
Nephros's next earnings report is expected for Mar 10, 2027.
Did NEPH beat earnings estimates last quarter?
Yes. Nephros reported EPS of $0.05 for the quarter ended Sep 30, 2026, above the $0.02 estimate, a 150.00% surprise.
What EPS do analysts expect from NEPH next quarter?
The consensus EPS estimate for Nephros for the quarter ending Dec 31, 2026 is $0.01 from 5 analysts, with estimates from $0.01 to $0.02.
How often does NEPH beat earnings estimates?
Nephros beat the EPS estimate in 7 of the 8 most recent quarters that had an estimate, with an average surprise of +225.00%.
NEPH pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors